Novartis: Hepatitis B, Chronic trials
The registry lists 23 Hepatitis B, Chronic studies with Novartis as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 2Phase 2 1Phase 3 10Phase 4 10No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus InfectionTerminatedNCT02058108Phase 3Results posted
- Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap ConceptCompletedNCT01379508Phase 4Results posted
- Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)TerminatedNCT00412750Phase 3Results posted
- Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis BCompletedNCT00412529Phase 3Results posted
- Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine StudiesCompletedNCT00142298Phase 3Results posted
- Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of CirrhosisCompletedNCT00076336Phase 3Results posted
- Epidemiological Study in Children and Adolescents With Chronic Hepatitis BCompletedNCT01163240
- Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection SubjectsTerminatedNCT00964665Phase 1/2
- Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis BCompletedNCT00907894Phase 1
- Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis BCompletedNCT00877149Phase 4
- Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 WeeksWithdrawnNCT00862706Phase 4
- Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis BCompletedNCT00781105Phase 4
- A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)CompletedNCT00651209Phase 4
- Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis BCompletedNCT00646503Phase 4
- Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With TelbivudineCompletedNCT00640588Phase 3
- Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis BWithdrawnNCT00606099Phase 4
- To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)CompletedNCT00537537Phase 4
- An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis BCompletedNCT00467545Phase 4
- Trial of Telbivudine Combination Therapy vs. Continued Adefovir MonotherapyWithdrawnNCT00409019Phase 4
- Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis BCompletedNCT00132652Phase 3
- Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis BCompletedNCT00131742Phase 3
- Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis BCompletedNCT00115245Phase 3
- A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis BCompletedNCT00057265Phase 3